150 related articles for article (PubMed ID: 37385277)
1. The pursuit of optimal semaglutide dosing in type 2 diabetes continues.
Sherrill CH; Hwang AY
Lancet; 2023 Aug; 402(10403):668-669. PubMed ID: 37385277
[No Abstract] [Full Text] [Related]
2. Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes.
Scheen AJ
Lancet Diabetes Endocrinol; 2020 May; 8(5):350-352. PubMed ID: 32333865
[No Abstract] [Full Text] [Related]
3. Oral semaglutide (Rybelsus) for type 2 diabetes.
Med Lett Drugs Ther; 2019 Oct; 61(1583):166-168. PubMed ID: 31770356
[No Abstract] [Full Text] [Related]
4. [The glucagon-like peptide-1 receptor-agonist semaglutide].
Boje AD; Juhl CR; Torekov SS; Madsbad S
Ugeskr Laeger; 2019 Oct; 181(41):. PubMed ID: 31610830
[TBL] [Abstract][Full Text] [Related]
5. Semaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes.
Blakely KK; Weaver K
Nurs Womens Health; 2020 Oct; 24(5):370-376. PubMed ID: 32890462
[TBL] [Abstract][Full Text] [Related]
6. Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese.
Slawson DC
Am Fam Physician; 2021 Jul; 104(1):96-97. PubMed ID: 34264618
[No Abstract] [Full Text] [Related]
7. Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus.
Semenya AM; Wilson SA
Am Fam Physician; 2020 Nov; 102(10):627-628. PubMed ID: 33179892
[No Abstract] [Full Text] [Related]
8. Efficacy of semaglutide versus liraglutide in clinical practice.
Goncalves E; Bell DS
Diabetes Metab; 2020 Nov; 46(6):515-517. PubMed ID: 31606525
[No Abstract] [Full Text] [Related]
9. Semaglutide: First Global Approval.
Dhillon S
Drugs; 2018 Feb; 78(2):275-284. PubMed ID: 29363040
[TBL] [Abstract][Full Text] [Related]
10. Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling.
Kalra S; Kalhan A; Berard L
Postgrad Med; 2020 Nov; 132(8):663-666. PubMed ID: 32781867
[No Abstract] [Full Text] [Related]
11. Semaglutide: new dawn for diabetics.
Memon A; Tehrim M; Kumari B
J Pak Med Assoc; 2023 Mar; 73(3):721. PubMed ID: 36932797
[No Abstract] [Full Text] [Related]
12. Practical guidance for use of oral semaglutide in primary care: a narrative review.
Morales J; Shubrook JH; Skolnik N
Postgrad Med; 2020 Nov; 132(8):687-696. PubMed ID: 32643514
[TBL] [Abstract][Full Text] [Related]
13. The evidence for oral semaglutide in type 2 diabetes from a managed care perspective.
Heile M; Taddei-Allen P
Am J Manag Care; 2020 Dec; 26(16 Suppl):S323-S324. PubMed ID: 33439580
[No Abstract] [Full Text] [Related]
14. Fathoming the Role of Semaglutide in Obesity Therapeutics.
George M; Balachandran K; Jinson J
Clin Ther; 2023 Aug; 45(8):804-805. PubMed ID: 37442659
[No Abstract] [Full Text] [Related]
15. Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes.
Basolo A; Fierabracci P; Salvetti G; Santini F
J Endocrinol Invest; 2024 May; 47(5):1047-1049. PubMed ID: 38157134
[No Abstract] [Full Text] [Related]
16. Switching from subcutaneous to oral semaglutide in type 2 diabetes: A prospective study.
Martínez-Montoro JI; Picón-César MJ; Generoso-Piñar M; Fernández-Valero A; López-Montalbán Á; Simón-Frapolli VJ; Hernández-Bayo J; Pinzón-Martín JL; Tinahones FJ
J Intern Med; 2024 Jan; 295(1):113-115. PubMed ID: 37902577
[No Abstract] [Full Text] [Related]
17. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
[TBL] [Abstract][Full Text] [Related]
18. Semaglutide Associated With Less Insulin Need in Early Type 1 Diabetes.
Harris E
JAMA; 2023 Oct; 330(14):1318. PubMed ID: 37728959
[No Abstract] [Full Text] [Related]
19. Once-Weekly Semaglutide in Adolescents with Obesity.
Malozowski S
N Engl J Med; 2023 Mar; 388(12):1145-1146. PubMed ID: 36947475
[No Abstract] [Full Text] [Related]
20. Once-Weekly Semaglutide in Adolescents with Obesity.
Snaith JR; Greenfield JR
N Engl J Med; 2023 Mar; 388(12):1145. PubMed ID: 36947474
[No Abstract] [Full Text] [Related]
[Next] [New Search]